Hot off the heating pad…BioEYES publishes our impact on over 19,000 students across the country. From 2010 to 2015, the team assessed students before and after our week-long experiments. Following a BioEYES class, all grade levels showed significant positive gains in learning. Interestingly, for all grade levels BioEYES increased students’ ability to imagine themselves as scientists. Check out the paper!
The Department of Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania seeks candidates for several Assistant Professor positions in the tenure track. Applicants must have an Ph.D. and/or M.D. degree and have demonstrated excellent qualifications in research.
Institute of Regenerative Medicine (IRM) investigators span the Schools of Medicine, Engineering, Veterinary Medicine, Dental Medicine, Arts & Sciences, and the Children’s Hospital of Philadelphia. We engage in inter-disciplinary research with the goals of understanding normal developmental and regenerative processes, modeling and studying human diseases, and developing diagnostics and medicines including cell and tissue therapeutics. More information about the IRM and its investigators can be found at http://irm.med.upenn.edu/.
The successful applicant will have experience in the fields of stem cell biology, neurogenesis, reprogramming, tissue engineering, and/or regenerative biology and medicine.
Applicants should have demonstrated outstanding success in research. We expect that successful candidates will apply innovative approaches to address fundamental questions in any area of relevance to the Institute. Research can be conducted in model organisms, human cells or organotypic cultures, or other cell systems.
Successful candidates are expected to develop extramurally funded research programs and be committed to the graduate education and outreach missions of the Institute.
First consideration will be given to applications received by October 15, 2016, but applications will be accepted after this date.
Dr. Ken Zaret, Director of the Institute for Regenerative Medicine is the Chair of the Search Committee.
We seek candidates who embrace and reflect diversity in the broadest sense.
The University of Pennsylvania is an EOE. Minorities/Women/Individuals with disabilities/Protected Veterans are encouraged to apply.
Apply for this position online here.
One of the most significant recent developments in cardiac research at Penn Medicine was achieved by mimicking the regeneration mechanisms of fish and frogs.
“A question that we have been asking for some time is how we can get the mammalian heart — the human heart in particular — to repair itself, since it doesn’t do it that well,” Ed Morrisey, PhD, professor of medicine, professor of cell and developmental biology, and scientific director of the Institute for Regenerative Medicine in the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, told Cardiology Today. “We started out with the idea that lower animals — for example, zebrafish — can do this quite readily.”
Cardiology Today about the heart muscle repair mechanisms of lower species, and how University of Pennsylvania researchers are incorporating these adaptations into human myocardial muscle regeneration.
Adult stem cells represent a sort of blank clay from which a myriad of different cell and tissue types are molded and as such are of critical importance to health, ageing and disease. In tissues that turn over rapidly, such as the intestines, the self-renewing nature of stem cells and their susceptibility to cancer-causing mutations has led researchers to postulate that these cells also act as the cell of origin in cancers. The rarity of adult stem cells relative to their differentiated daughter cells has, however, made them historically difficult to study.
Over the years, researchers have hypothesized that the body maintains a population of mutation- and injury-resistant “reserve” stems cells that serve as a kind of dormant reservoir from which all other cells in a given tissue can be derived. Yet researchers have been conflicted about the precise identity of this population of cells.
Now, a team from the University of Pennsylvania has helped identify key characteristics that distinguish reserve stem cells from other stem cell populations that had been purported to have similar properties. The work, which employed single-cell gene expression analyses as well as other cutting-edge techniques, demonstrated that, in the intestines, reserve stem cells are a distinct population from so-called “label-retaining cells.” The two populations were long believed to be one and the same.
“The devil is in the details,” said senior author Christopher J. Lengner, an assistant professor in the Department of Biomedical Sciences in Penn’sSchool of Veterinary Medicine and member of the Penn Institute for Regenerative Medicine. “You need an assay with single-cell sensitivity to address the potential heterogeneity in the cell population being study and thus to truly understand what these cells are. Now that we have that level of resolution, we can begin to ask questions that are relevant to questions such as how cancer is initiated, a process that starts in a single cell.”
Read the full article here.
The paper appears in the journal Gastroenterology.
PHILADELPHIA—Asthma is an enormous public health problem that continues to grow larger, in part because scientists don’t fully understand how it is caused. Existing therapies don’t cure the disease and often don’t even significantly alleviate the symptoms. Now, scientists from the Perelman School of Medicine at the University of Pennsylvania and Rutgers University have identified a biological pathway that potentially explains why current asthma therapies don’t work well in many cases—and might be targeted to help those patients.
Asthma is a chronic condition that affects more than 25 million people in the United States alone, including more than 7 million children. It accounts for nearly 2 million ER visits annually and about 1.5 million patient-days of hospital inpatient care.
“Only 60 percent of asthma patients have an inflammatory or allergic component to their asthma and 40 percent of asthma patients wheeze in part due to intrinsic abnormalities of epithelial and smooth muscle cells,” said co-senior author Edward E. Morrisey, PhD, a professor of Cell and Developmental Biology and director of the Penn Center for Pulmonary Biology at Penn.
Read the full story here.
This spring, the BioEYES program celebrates a major milestone: It will serve its 100,000th student.
That means in the 14 years since BioEYES began, 100,000 elementary, middle, and high school students from Philadelphia and four other sites have been exposed to innovative, hands-on lessons that get them excited about and interested in science.
That’s a lot of students. And that’s a lot of zebrafish.
The zebrafish are at the center of the BioEYES program: Live fish are brought into the classroom, and for a week, students observe the embryos and larvae, recording what they see, hypothesizing and testing ideas, and asking questions. In short, they learn to think and act as scientists do.
“Students get to be scientists and not just learn from scientists—they have to take ownership of the scientific process,” explains Jamie Shuda, director of outreach and education at the Institute for Regenerative Medicine, and the co-founder of BioEYES. “We’re across grade spans but we are specific to what teachers have to teach. It’s not an addition, but a complement to what we’re asking students to master.”
Read the full story on the Penn Current here.
A study from researchers at The Children’s Hospital of Philadelphia may add new lines to the textbook description of how cancer cells divide uncontrollably and develop into tumors. Their study, published in Nature Communications, identifies and describes an epigenetic mechanism in cancer cells that amplifies the expression of many genes and could be a central hub in cancer cell growth. Unlike most molecular cancer discoveries that advance knowledge of the disease by dividing it into narrower subtypes, this finding could directly apply to multiple cancer types.
“We know the signaling pathway known as the Rb pathway is altered in pretty much every single tumor that you can find in clinical settings,” said Patrick Viatour, PharmD, PhD, the study’s senior author, an investigator at CHOP, assistant professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, and member of the Institute for Regenerative Medicine.
View the full story here.
Scientists say gene editing holds the key to curing a host of intractable diseases, including cystic fibrosis, HIV, cancer, and cataracts, to name a few. Policymakers fear that, if this key fell into the wrong hands, it could open a Pandora’s box of dangers such as eugenics and performance enhancements on demand. Two Penn Integrates Knowledge professors who are experts in the field recently discussed these pressing issues with Dan Loney on Wharton Business Radio.
James W. Effron University Professor John Gearhart, who holds appointments in thePerelman School of Medicine (PSOM) and in the School of Veterinary Medicineand has served as director of Penn’s Institute for Regenerative Medicine, discovered how to isolate and propagate the world’s first human pluripotent stem cells in 1998.
Read the full story here.
Anil K. Rustgi, MD, Chief of Gastroenterology in the Perelman School of Medicine at the University of Pennsylvania, IRM Co-Program Leader in Digestive and Liver Diseases and Program Leader of the ACC Tumor Biology Program is once again the recipient of a prestigious Research Professor Award from the American Cancer Society (ACS).